Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.39 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3823520 | 0.88 | RXFP1 (0.49) | ALDH1A1KCNJ1NPC1KCNH2 | |
| SCHEMBL3234164 | 0.85 | APLNR (0.52) | ALDH1A1KCNJ1P4HTMAPLNRNPC1 | |
| SCHEMBL14815618 | 0.84 | GRIN1 (0.45) | ALDH1A1KCNJ1P4HTMNPC1GAA | |
| SCHEMBL17447442 | 0.80 | P4HTM (0.42) | ALDH1A1P4HTMAPLNRNPC1GAA | |
| SCHEMBL30449388 | 0.80 | P4HTM (0.59) | ALDH1A1P4HTMSMN1; SMN2P4HA1MIF | |
| SCHEMBL110129 | 0.80 | P4HTM (0.59) | ALDH1A1P4HTMSMN1; SMN2P4HA1MIF | |
| SCHEMBL15440496 | 0.80 | P4HTM (0.42) | ALDH1A1P4HTMAPLNRNPC1GAA | |
| SCHEMBL31474565 | 0.78 | P4HTM (0.57) | ALDH1A1P4HTMSMN1; SMN2P4HA1MIF | |
| SCHEMBL30074643 | 0.78 | KMT2A (0.58) | ALDH1A1P4HTMAPLNRKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL5223155 | 0.78 | P4HTM (0.57) | ALDH1A1P4HTMSMN1; SMN2P4HA1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983073-A1 | SUBSTITUTED PYRAZOLO[4,3-B]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | claimed |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735423-A1 | KV7 MODULATORS | Saniona A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12351581-B2 | Compounds for FGFR inhibition | COGENT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025034912-A9 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250066352-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2008039139-A1 | NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039139-A1 | NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039138-A1 | NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039138-A1 | NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| EP-1899323-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| WO-2006123113-A2 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | WO | disclosed |
| EP-1716127-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005082871-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | ALDH1A1 259/4885KCNJ1 1462/4885P4HTM 3107/4885 |
| US-20250066352-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | ALDH1A1 1423/4885KCNJ1 3729/4885P4HTM 1665/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | ALDH1A1 785/4885KCNJ1 211/4885P4HTM 934/4885 |
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | ALDH1A1 1423/4885KCNJ1 3729/4885P4HTM 1665/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | ALDH1A1 780/4885KCNJ1 4151/4885P4HTM 3791/4885 |
| US-12351581-B2 | Compounds for FGFR inhibition | FGFR1, FGFR4, FGFR3 | ALDH1A1 1423/4885KCNJ1 3729/4885P4HTM 1665/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | ALDH1A1 2830/4885KCNJ1 3745/4885P4HTM 2278/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | ALDH1A1 244/4885KCNJ1 3774/4885P4HTM 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.